Biochemical strategies to anticoagulation: A comparative overview

Current Vascular Pharmacology

Volumn 2, Issue 3, 2004, Pages 199-228

  Chu, Arthur J ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANTOU UNIVERSITY   (China)

Author keywords

Anticoagulant; FVII; FX; Hypercoagulability; Inflammation; Thrombin; Thrombosis; Tissue factor

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 4H 3,1 BENZOXAZIN 4 ONE DERIVATIVE; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID METHANESULFONATE; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; APOLIPOPROTEIN B100; BEMIPARIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A INHIBITOR; BOTHROJARACIN; CEDARLANE; CONCANAVALIN A; DEXTRAN SULFATE; DX 9065 A; ENOXAPARIN; HEPARIN; HEPARIN COFACTOR II; LIPOPROTEIN; MARCKS PROTEIN; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; PROTEIN S; REVIPARIN; SERINE PROTEINASE INHIBITOR; SPHINGOSINE; THROMBIN INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOWNSTREAM PROCESSING; DRUG PROTEIN BINDING; ENZYME ACTIVATION; HOMEOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; IN VIVO STUDY; LEUKEMIA; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SEPSIS; SIGNAL TRANSDUCTION; THALASSEMIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION;

EID: 3042696879     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043385673     Document Type: Review

References (506)

1. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
2. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal indicator of blood coagulation. Thromb Res 1996; 81: 1-41.
3. Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 8: 385-90.
4. Chai SJ, Macik BG. Improving the safety profile of Warfarin. Semin Hematol 2002; 39: 179-186.
5. Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost 2001; 86: 488-498.
6. Weitz JI. Low-molecular-weight-heparins. N Engl J Med 1997; 337: 688-98.
7. Kaiser B, Hoppensteadt DA, Fareed J. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drug 2001; 10: 1925-1935.
8. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29: S48-S51.
9. Griffin JH, Zlokovic B, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thromosis and stroke. Semin Hematol 2002; 39: 197-205.
10. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002; 39: 187-96.
11. Turpie AGG. Pentasaccharides. Semin Hematol 2002, 39, 158-71.
12. Samama MM. Synthetic direct and indirect factor Xa inhibitor. Thromb Res 2002; 106: V267-73.
13. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
14. Giesen PLA, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-84.
15. Wildgoose P, Berkner KL, Kisiel W. Synthesis, purification and characterization of an Arg 152-Glu site-directed mutant of recombinant human blood clotting factor VII. Biochemistry 1990; 29: 3413-20.
16. Gailani D. Activation of Factor IX by factor XIa. Trends Cardiovasc Med 2000; 10: 198-204.
17. Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb 1980; 5: 245-90.
18. Chu AJ, Raphael UO, Prasad JK, Beydoun S, Ramos N. II. Compound 48/80 suppresses monocytic tissue factor-initiated extrinsic blood coagulation induced by bacetrial endotoxin. J Surg Res 1999; 87: 252-7.
19. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, adhesive, and proinflammatory attributes. Blood 1997; 90; 3819-43.
20. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulantion-factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
21. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congential clotting factor abnormalilties and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine 1983; 62: 248-55.
22. Harris MG, Exner T, Rickard KA, Kronenberg H. Multiple cerebral thrombosis in Fletcher factor (prekallikerin) deficiency: a case report. Am J Hematol 1985; 19: 387-93.
23. Motta G, Rojkjaer R, Hasan AA, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallilrein assembly and activation on endothelial cells: a novel mechansism for contact activation. Blood 1998; 91: 516-28.
24. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-6.
25. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22.
26. Kitchens GS. The contact system. Arch Pathol Lab Med 2002; 126: 1382-86.
27. Vaya A, Mira Y, Martinez M, Villa P, Ferrando F, Estelles A, et al. Biological risk factors for deep vein thrombosis. Clin Hemorheol Microcirc 2002; 26: 41-53.
28. Levy PJ, Gonzales FM, Rush DS, Haynes JL. Hypercoagulable states as an evolving risk for spontaneous venous and arterial thrombosis. J Am Coll Surg 1994; 178: 266-70.
29. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-44.
30. Barczyk A, Pierzchala W. Risk factors of venous thromboembolism. Wiad Lek 2001; 54: 311-24.
31. Lee RW. Pulmonary embolism. Chest Surg Clin N Am 2002; 12: 417-37.
32. Subar M. Clinical evaluation of hypercoagulable states. Clin Geriatr Med 2001; 17: 57-70.
33. Rossi ML, Merlini PA, Ardissino D. Laboratory markers of hypercoagulability. Ital Heart 2001; 2: 490-4.
34. Takamiya O, Okumura N, Factor VII for a molecular marker in hypercoagulable state. Rinsho Byori 1993; 41: 83-7.
35. Penick GD, Dejanov II, Roberts HR, Webster WP. Elevation of factor 8 in hypercoagulable state. Thromb Diath Haemorrh Suppl 1996; 20: 39-48.
36. Fyman PN, Gotta A, Casthely PA, Griepp R, Ergin MA, Goodman K. Factor IX induced hypercoagulable state. Anesthesiology 1985; 62: 515-6.
37. Wessler S, Yin ET. Experimental hypercoagulable state induced by factor X: comparison of the nonaciivated and activated forms. J Lab Clin Med 1968; 72: 256-60.
38. Lowe GDO, Rumley A. Fibrinogen and its degradtion products as thrombotic risk factors. Ann N Y Acad Sci 2001; 936: 560-5.
39. Dahl OE. Mechanisms of hypercoagulability. Thromb Haemost 1999; 82: 902-6.
40. Chandler WL, Rodgers GM, Sprouse JT, Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 2002; 126: 1405-14
41. Dempfle CE. Use of D-dmer assays in the diagnosis of venous thrombosis. Semin Thromb Hemost 2000; 26: 631-41.
42. Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable state. Br J Haematol 1989; 71: 65-70.
43. Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotani C, et al. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in aterial fibrillation. Blood Coagul Fibrinolysis 1992; 3: 469-73.
44. Matsuo T, Kario K, Matsuo M. Thrombin-antithrombin III complex. Rinsho Byori 1991; 39: 701-6.
45. Gando S, Nanzaki S, Morimoto Y, Ishitani T, Kemmotsu O. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med 2001; 29: 262-6.
46. Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 605-17.
47. Jafri SM, Mammen EF, Masura J, Goldstein S. Effect of warfarin on markers of hypercoagulability in patients with heart failure. Am Heart J 1997; 134: 27-36.
48. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997; 23: 543-5.
49. Gorog DA, Rakhit R, Parums D, Laffan M, Davies GJ. Raised factor VIII is associated with coronary thrombotic events. Heart 1998; 80: 415-7.
50. El-Hazmi MA. Hematological risk factors for coronary heart disease. Med Princ Pract 2002; 11: 56-62.
51. Miller MA, Spillert CR, Ponnudurai R, Bonthu S, Lazaro EJ. Are hypertensives hypercoagulable? J Natl Med Assoc 1995; 87: 71-2.
52. Lip GY, Li-Saw-Hee FL. Does hypertension confer a hypercoagulable state? J Hypertens 1998; 16: 913-6.
53. Lip GY. Hypertension and the prothrombotic state. J Hum Hypertens; 2000; 14: 687-90.
54. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33: 1424-6.
55. Arkhangel'ski AV, Kovalev VI. Disseminated intravascular coagulation syndrome in myocardial infarct. Kardiologiia 1993; 33: 37-40.
56. Gowda MS, Zucker ML, Vacek JL, Carriger WL, Van Laeys DL, Rachel JM, et al. Incidence of factor V Leiden in patients with acute myocardial infarction. J Thromb Thrombolysis 2000; 9: 43-5.
57. Redondo M, Watzke HH, Stucki B, Sulzer I, Biasiutti FD, Binder BR, et al. Coagulation factor II, V, VII, X, prothrombin gene 20210G/A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
58. Bottiger BW, Motsch J, Bohrer H, Boker T, Aulmann M, Nawroth PP, Martin E. Activation of blood coagulation after cardiac arrest is not balanced adequately by activation of endogenous fibrinolysis. Circulation 1995; 92: 2572-8.
59. Kaplan KL, Bini A. Thrombosis in atherogenesis. Crit Rev Oncol Hematol 1989; 9: 305-18.
60. Thompson WD, Smith EB, Stirk CM, Kochhar A. Atherosclerotic plaque growth: presence of stmulatory fibrin degradation products. Blood Coagul Fibrinolysis 1990; 1: 489-93.
61. Warkentin TE. Hemostasis and atherosclerosis. Can J Cardiol 1995;11:29C-34C.
62. Sueishi K, Ichikawa K, Kato K, Nakagawa K, Chen YX. Atherosclerosis: coagulation and fibrinolysis. Semin Thromb Hemost 1998; 24: 255-60.
63. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000; 75: 369-80.
64. Giannitsis E, Siemens HJ, Mitusch R, Tettenborn I, Wiegand U, Schmucker G, et al. Prothrombin fragments F1+2, thrombin-antithrombin III complexs, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int J Cardiol 1999; 68; 269-74.
65. Westmuckett AD, Lupu C, Goulding DA, Das S, Kakkar VV, Lupu F. In situ analysis of tissue factor-dependent thrombin generation in human atherosclerotic vessels. Thromb Haemost 2000; 84: 904-11.
66. Jaffer AF, Tung C-H, Gerszten RE, Weissleder R. In vivo imaging of thrombin activity in experimental thrombi using a thrombin-sensitive near-infrared molecular probe. Arterioscler Thrmob Vasc Biol 2002; 22: 1929-35.
67. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GD, Fowkes FG. Plasma fibrinogen, haemostatic factors and predication of peripheral arterial disease in the Edinburgh Artery Study. Blood Coagul Fibrinolysis 2000; 11: 43-50.
68. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999: 81: 165-176.
69. Smith EB, Thompson WD, Crosbie L, Stirt CM. Fibrinogen/fibrin in athersclerosis. Eur J Epidemiol 1992; 8: 83-7.
70. Naito M, Stirk CM, Smith EB, Thompson WD. Smoth muscle cells outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis. Thromb Res 2000; 98: 165-74.
71. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogeneis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-97.
72. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, et al. Lpiprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link. between lipoproteins and thrombosis. Blood 2001; 98: 2980-87.
73. Edelberg J, Pizzo SV. Lipoprotein (a) regulates plasmin generation and inhibition. Chem Phys Lipids 1994; 67/68: 363-8.
74. Undas A, Domagala TB, Jankowski M, Szczeklik A. Treatment of hyperhomocysteinemia with folic acid and vitamin B12 and B6 attenuates thrombin generation. Thromb Res 1999; 95: 281-8.
75. Klerk M, Verhoef P, Verbruggen B, Schouten EG, Blom HJ, Bos GM, et al. Effect of homocysteine reduction by B-vitamin supplementation on markers of clotting activation. Thromb Haemost 2002; 88: 230-5.
76. Ratnoff OD. Activation of Hageman factor by L-homocysteine. Science 1968; 162: 1007-9.
77. Rodgers GM, Kane WH. Activation of endogenous factor V by homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-16.
78. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM Homocysteine, a risk for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arteriosclerosis Thromb 1993; 13: 1327-33.
79. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
80. Lentz SR, Sadler JE. Inhibiton of thrombomodulin surface expression and protein C activation by the thromgenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
81. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-36.
82. Giannini MJ, Coleman M, Innerfield I. Antithrombin activity in homocystinuria. Lancet 1975; I: 1094.
83. Nishinaga M, Ozawa T, Shimada K. Homocytsteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-6.
84. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91 2873-79.
85. Midorikawa S, Sanada H, Hashimoto S, Watanabe T. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells. Biochem Biophys Res Commun 2000; 272: 182-5.
86. Tofler GH, D'Agostino RB, Jacques PF, Bostom AG, Wilson PW, Lipinska I, et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Haemost 2002; 88: 799-804.
87. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 116: 754-61.
88. Lane DA, Kunz G, Olds RJ, Thein SL. Molecular genetics of antithrombin deficiency. Blood Rev 1996; 10: 59-74.
89. Broekmans AW. Hereditary protein C deficiency. Hemostasis 1985; 15: 233-40
90. Comp PC, Nixon R, Cooper M, Esmon C. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74; 2082-8.
91. Schwartz H, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasmal protein S deficiency in familiar thrombotic disease. Blood 1984; 64: 1297-1300.
92. Allaart CF, Aronson D, Ruys T. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990; 64: 206-10.
93. Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost 1997; 78: 351-6.
94. Kondo S, Tokunaga F, Kario K, Matsuo T, Koide T. Molecular and cellular basis for type I heparin cofactor II deficiency. Blood 1996; 87: 1006-12.
95. Tollefsen DM. Heparin cofactor II deficiency. Arch Pathol Lab Med 2002; 126: 1394-1400.
96. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002; 126: 1281-95.
97. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330; 517-22.
98. Dahback B. Resistance to activated protein C caused by the R506Q mutantion in the gene for factor V is a common risk factor for venous thrombosis. J Intern Med 1997; 740(S): 1-8.
99. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
100. Kyrle PA, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
101. Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1996; 78: 467-70.
102. White B, Perry D. Acquired antithrombin III deficiency in sepsis. Br J Haematol 2001; 112: 26-31.
103. Noda A, Wada H, Kusiya F, Sakakura M, Onishi K, Nakatani K, et al. Plasma levels of heparin cofactor II (HC II) and thrombin-HC II complex in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2002; 8: 265-71.
104. Clark P, Walker ID. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115: 767-71.
105. Field SL, Brighton TA, McNeil HP, Chesterman CN. Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12: 407-22.
106. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diab Complications 2001; 15: 44-54.
107. Callesr-Escandon J, Garcia-Rubi E, Mirza S, Mortensen A. Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis 1999; 10: 23-30.
108. Yamada T, Sato A, Nishimori T, Mitsuhashi T, Terao A, Saai H, et al. Importance of hypercoagulabiliey over hyperglycemia for vascular complication in type 2 diabetes. Diabetes Res Clin Pract 2000; 49: 23-31.
109. Massi-Benedetti M, Federici MO. Cariovascular risk factors in type 2 diabetes: the role of hyperglycaemia. Exp Clin Endocrinol Diabetes 1999; 107: S120-3.
110. Acang N, Jalil FD. Hypercoagulation in diabetes mellitus. Southeast Asian J Trop Med Public Health 1993; 24: 263-6.
111. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643-54.
112. Gosk-Bierska I, Adamiec R, Alexewicz P, Wysokinski WE. Coagulation in diabetic and non-diabetic claudicants. Int Angiol 2002; 21:128-33.
113. Patrassi GM, Martinelli S, Picchinenna A, Girolami A. Contact phase of coagulation in diabetes mellitus after aspirin administration. Folia Haematologica 1985; 112: 333-8.
114. Ceriello A, Quatraro A, Marchi E, Barbanti M, Dello E, Russo P, et al. The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. Diabet Med 1990; 7: 343-8.
115. Alakhverdian R, Koev D. Fibrinogen-fibrin degradation products in diabetes mellitus. Vutr Boles 1987; 26: 72-5.
116. Lupu C, Calb M, Ionescu M, Lupu F. Enhanced prothrombin and intrinsci factor X activation on blood platelets from diabetic patients. Thromb Haemost 1993; 70: 579-83.
117. Ichikawa K, Yoshinari M, Iwase M, Wakisaka M, Doi Y, Iino K, et al. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 1998; 136; 281-7.
118. Reverter JL, Reverter JC, Tassies D, Rius F, Monteagudo J, Rubies-Prat J, et al. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol 1997; 56: 93-9.
119. Ceriello A, Taboga C, Giacomello R, Falleti E, De Stasio G, Motz E, et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994; 43: 430-2.
120. Koert M, Nowak-Gotl U, Kreuz W, Gruttner HP, Kornhuber B, Breddin HK. 15 parameters of coagulation and fibrinolysis in children with type I diabetes mellitus (onset period). Klin Padistr 1991; 203: 429-32.
121. Myrup B, Rossing P, Jensen T, Gram J, Kluft C, Jespersen J. Procoagulant activity and intimal dysfunction in IDDM. Diabetologia 1995; 38:73-8.
122. Leurs PB, van Oerle R, Wolffenbuttel BH, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Res 1997; 77: 472-6.
123. Duboscq C, Quintana I, Barros J, Kordich L. Heparin cofactor II in diabetic patients. Blood Coagul Fibrinolysis 1994; 5: 201-4.
124. Vukovich TC, Schernthaner G. Decreased proteins C levels in patients with insulin-dependent type I diabetes mellitus. Diabetes 1986; 35: 617-9.
125. Myrup B, Jensen T, Gram J, Kluft C, Jespersen J, Deckert T. No effect of unfractioned or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy. Diabetes Care 1997; 20: 1615-19.
126. Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 2000; 14: 121-6.
127. Sumida Y, Wada H, Fujii M, Mori Y, Nakasaki T, Shimura M, et al. Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 1997; 8: 303-7.
128. Davi G, Gennaro F, Spatola. A, Catalano I, Averna M, Montalto G, et al. Thrombin-antithrombin III complex in Type II diabetes mellitus. J Diabetes Complications 1992; 6: 7-11.
129. Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, et al. Hypercoagulability and high lipoprotein (a) levels in patients with Type II diabetes mellitus. Atherosclerosis 1996; 120: 7-14.
130. Fujiwara Y, Tagami S, Kawakami Y. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. J Atheroscler Thromb 1998; 5: 21-8.
131. Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 dabetes: association with increased plasminogen activator inhibitor-1. Metabolism 2002; 51: 471-6.
132. Oida K, Takai H, Maeda H, Takahashi S, Tamai T, Nakai T, et al. Plasma thrombomodulin concentration in diabetes mellitus. Diabetes Res Clin Pract 1990; 10: 193-6.
133. Rigla M, Fontcuberta J, Mateo J, Caixas A, Pou JM, de Leiva A, et al. Physical training decreases plasma thrombomodulin in type I and type II diabetic patients. Diabetologia 2001; 44: 693-9.
134. Samad F, Pandey M, Loskutoff DJ. Regulation of tissue factor gene expression in obesity. Blood 2001; 98: 3353-8.
135. Small M, Douglas JT, Lowe GD, MacCuish AC, Forbes CD. Effect of insulin therapy on coagulation and platelet function in type II (non-insulin-dependent) diabetes mellitus. Haemostasis 1986; 16: 417-23.
136. Song KS, Kim HS, Park KE, Kwon OH. The fibrnogen degradation products (FgDP) levels in liver disease. Yonsei Med J 1993; 34: 234-8.
137. Bell H, Odegaard OR, Andersson T, Raknerud N. Protein C in patients with alcoholic cirrhosis and other liver diseases. J Hepatol 1992; 14: 163-7.
138. Kemkes-Matthes B, Bleyl H, Matthes KJ. Coagulation activation in liver diseases. Thromb Res 1991; 64: 253-61.
139. Violi F, Ferro D, Basili S, Artini M, Valesini G, Levrero M, Cordova C. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med 1995; 43: 550-4.
140. den Ouden M, Ubachs JM, Stoot JE, van Wersch JW. Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours. Scan J Clin Lab Invest 1998; 58: 555-9.
141. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-5.
142. Yamada A, Wada H, Kamikura Y, Hiyoyama K, Shimura M, Nagaya S, et al. Plasma levels of activated FVII in various diseases. Blood Coagul Fibrinolysis 1996; 7: 794-8.
143. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol 2001; 106: 33-42.
144. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998; 102: 889-95.
145. Reddy VB, Kowal-Vern A, Hoppensteadt DA, Kumar A, Walenga JM, Fareed J, et al. Global and molecular hemostatic markers in acute myeloid leukemia. Am J Clin Pathol 1990; 94: 397-403.
146. Nakasaki T, Wada H, Watanabe R, Mori Y, Gabazza EC, Kageyama S, et al. Elevated tissue factor levels in leukemic cell homogenate. Clin Appl Thromb Hemost 2000; 6: 14-7.
147. Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freed S, Boggio L, et al. Coagulation changes in individuals with sickle cell trait. Am J Hematol 2002; 69: 89-94.
148. Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cells patients. Br J Haematol 1992; 81: 539-44.
149. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-23.
150. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994; 71: 169-72.
151. Marfaing-Koka A, Boyer-Neumann C, Wolf M, Leroy-Matheron C, Cynober T, Tchernia G. Decreased protein S activity in sickle cells disease. Nouv Rev Fr Hematol 1993; 35: 425-30.
152. Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15: 15-24.
153. Toulon P, Lamine M, Ledjev I, Guez T, Holleman ME, Sereni D, Sicard D. Haparin cofactor II deficiency in patients infected with the human immunodeficiency virus. Thromb Haemost 1993; 70: 730-5.
154. Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: Correlation with advanced disease in HIV-1-infected patients. J Acquit Immune Defic Syndr 1992; 5: 484-9.
155. Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1: 786-90.
156. Jastrzebska M, Przybycien K, Chelstowski K, Torbus-Lisiecka B, Kornacewicz-Jach Z, Naruszewicz M. Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography. Nutr Metab Cardiovasc Dis 1999; 9: 33-40.
157. Mukherjee M, Dawson G, Sembhi K, Kakkar VV. Correction of circulating 17 beta-oestradiol with haemostatic factors in healthy postmenopausal women. Thromb Haemost 1996: 76: 500-1.
158. Porreca E, Di Febbo C, di Castelnuovo A, Bcante G, Amore C, Angelini A, et al. Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. Atherosclerosis 2002; 165: 159-63.
159. Puccetti L, Bruni F, Di Renzo M, Bova G, Cercignani M, Iadanza A, et al. Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivasstatin. Eur Rev Med Pharmacol 1999; 3: 197-204.
160. Regeczy N, Balogh I, Lakos G, Zeher M, Bodolay E, Szucs G, et al. Hypercoagulability in various autoimmune dieascs: no association with factor V Leiden mutation. Haematologia 2000; 30: 35-9.
161. Eldor A, Maclouf J, Lellouche F, Ben-Yashar V, Barenholz Y, Durst R, et al. A chronic hypercoagulable state and life-long platelet activation in beta thelessamia major. Southeast Asian J Trop Med Public Health 1993; 24: 92-5.
162. Eldor A, Rachmilewitz E. The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
163. Cheras PA, Whitaker AN, Blackwell EA, Sinton TJ, Chapman MD, Peacock KA. Hypercoagulability and hypofibrinolysis in primary osteoarthritis. Clin Orthop 1997; 334: 57-67.
164. Biron C, Bengler C, Gris JC, Schved JF. Acquired isolated factor VII deficiency during sepsis. Haemostasis 1997; 27: 51-6.
165. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Ned 2001; 29: S0-90-4.
166. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-35.
167. Walker ID. Thrombophilia in pregnancy. J Clin Pathol 2002; 53: 573-80.
168. Enriquez R, Rondini C, Sanchez A, Montes C, Poblete J. A, Neira J, et al. Congenital defects of antithrombin III and protein C and S during pregnancy. Rev Med Chil 1999; 127: 171-80.
169. Dalaker K, Prydz H. The coagulation factor VII in pregnancy. Br J Haematol 1984; 56: 233-41.
170. Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997; 73: 31-6.
171. Weiner CP, Kwaan H, Hauck WW, Duboe FJ, Paul M, Wallemark CB. Fibrin generation in normal pregnancy. Obstet Gynecol 1984; 64: 46-8.
172. Pinto S, Abbate R, Rostagno C, Bruni V, Rosati D, Neri Serneri GG. Increased thrombin generation in normal pregnancy. Acta Eur Fertil 1988; 19: 263-7.
173. Dunjic R, Elezovic I, Rakic S, Milovic Z, Loncar-Stevanovic H. Protein S and pregnancy. Srp Arh Celok Lek 2002; 130: 36-7.
174. Janku K, Penka MA hypercoagulation syndrome in pregnancy due to an antithrombin III defect. Cesk Gynecol 1990; 55: 657-60.
175. Yamada H, Kato EH, Kobashi G, Ebina Y, Shimada S, Morikawa M, et al. Recurrent pregnancy loss: etiology of thrombophilia. Semin Thromb Hemost 2001; 27: 121-9.
176. Norris LA, Bonnar J. Haemostatic changes and the oral contraceptive pill. Baillieres Clin Obstet Gynaecol 1997; 11: 545-64
177. Inauen W, Baumgartner HR, Haeberli A, Straub PW. Excessive deposition of fibrin, platelets and platelet thrombi on vascular subendothelium during contraceptive drug treatment. Thromb Haemost 1987; 57: 306-9.
178. Buccino G, Scoditti U, Pini M, Tagliaferri AR, Manotti C, Mancia D. Low-oestrogen oral contraceptives as a major risk factor for cerebral venous and sinus thrombosis: evidence from a clinical series. Ital J Neurol Sci 1999; 20: 231-5.
179. Holschermann H, Terhalle HM, Zakel U, Maus U, Parviz B, Tillmanns H, et al. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. Thromb Haemost 1999; 82: 1614-20.
180. Kelleher CC. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostasis system: relation to the development of cardiovascular disease. Am J Obstet Gynecol 1990; 163: 392-5.
181. Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-84.
182. Winkler UH. Activated protein C resistance and deficiencies of antithrombin III, protein C or protein S and the risk of thromboembolic disease in users of oral contraceptives. Eur J Contracept Reprod Health Care 1998; 3: 65-74.
183. Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 1999; 5: 672-80.
184. Kluft C. Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies. Curr Med Chem 2000; 7: 585-91.
185. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95: 193-7.
186. Lebech AM, Kjaer A. Lipid metabolism and coagulation during the normal menstrual cycle. Horm Metab Res 1989; 21: 445-8.
187. Gottsater A, Rendell M, Hulthen UL, Berntorp E, Mattiasson I. Hormone replacement therapy in healthy postmenpausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med 2001; 249: 237-46.
188. Mukherjee M, De Lorenzo F, Kadziola Z, Rutlin A, Ranlall N, Sembhi K, et al. Triglycride dependence of factor VII coagulant activity in deep venous thrombosis. Haemostasis 1999; 29: 336-42.
189. Kim HC, Kemmann E, Shelden RM, Saidi P. Response of blood coagulation parameters to elevated endogenous 17 beta-estradiol levels induced by human menopausal gonadotropins. Am J Obstet Gynecol 1981; 140: 807-10.
190. Bonduki CE, Lourenco DM, Baracat E, Haidar M, Noguti MA, da Motta EL, et al. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet Gynecol Scand 1998; 77: 330-3.
191. van Ommen CH, Fijnvandraat K, Vulsma T, Delemarre-Van De Waal HA, Peters M. Acquired protein S deficiency caused by estrogen treatment of tall stature. J Pediatr 1999; 135: 477-81.
192. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost 2001; 27: 585-92.
193. Engelaman DT, Gabram SG, Allen L, Ens GE, Jacobs LM. Hypercoagulability following multiple trauma. World J Surg 1996; 20:5-10.
194. Johna S, Cemaj S, O'Callaghan T, Catalano R.Effect of tissue injury on D-Dimer levels: a prospective study in trauma patients. Med Sci Monit 2002; 8: CR5-CR8.
195. Seyfer AE, Seaber AV, Dombrose FA, Urbaniak JR. Coagulation changes in elective surgery and trauma. Ann Surg 1981; 193: 210-3.
196. Utter GH, Owings JT, Jacoby RC, Gosselin RC, Paglieroni TG. Injury induces increased monocyte expression of tissue factor: factors associated with head injury attenuate the injury-related monocyte expression of tissue factor. J Trauma 2002; 52: 1071-7.
197. Komuro Y, Sekiguchi J, Nomurs S, Ohmori K, Takasugi Y, Arai C. Blood coagulation activity during microsurgery. Ann Plast Surg 1998; 40: 53-8.
198. Kang J, Kambayashi J, Sakon M, Tsujinaka T, Mori T. Postoperative changes in hemostasis analyzed by the serial determination of fibrinopeptides and D-dimer. Jpn J Surg 1989; 19: 262-8.
199. Andersson TR, Berner NS, Larsen ML, Odegaard OF, Abildgaard U. Plasma heparin cofactor II, protein C and antithrombin in elective surgery. Acta Chir Scand 1987; 153: 291-6.
200. Turner-Gomes SO, Mitchell L, Williams WG, Andrew M. Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1994; 107: 562-8.
201. Chan AK, Leaker M, Burrows FA, Williams WG, Gruenwald CE, Whyte L, et al. Coagulation and fibrinolytic profile of pediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997; 77: 270-7.
202. Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin generation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1997; 113: 576-84.
203. Philippou H, Adami A, Davidson SJ, Pepper JR, Burman JF, Lane DA. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 2000; 84: 124-8.
204. De Somer F, Van Belleghem Y, Caes F, Francois K, Van Overbeke H, Arnout J, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002; 123: 951-8.
205. Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003; 101: 4355-62.
206. Giangrande PL. Air travel and thrombosis. Int J Clin Pract 2001; 55: 690-3.
207. Bendz B, Rostrup M, Sevre K, Andersen TO, Sandset PM. Association between acute hypobaric hypoxoa and activation of coagulation in human beings. Lancet 2000; 356: 1657-8.
208. Nakanishi K, Tajima F, Nakata Y, Osada H, Ogata K, Kawai T, et al. Tissue factor is associated with the nonbacterial thrombotic endocarditis induced by a hypobaric hypoxic environment in rats. Virchows Arch 1998; 433: 375-9.
209. Bendz B, Sevre K, Andersen TO, Sandset PM. Low molecular weight heparin prevents activation of coagulation in a hypobaric environment. Blood Coagul Fibrinolysis 2001; 12: 371-4.
210. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framington Study. Am Heart J 1987; 113: 1006- 10.
211. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97: 785-97.
212. Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J 1994; 128: 7-11.
213. El-Sayed MS, Nieuwenhuizen W. The effect of alcohol ingestion on the exercise-induced changes in fibrin and fibrinogen degradation products in man. Blood Coagul Fibrinolysis 2000; 11: 359-65.
214. Miller GJ. Dietary fatty acids and blood coagulation. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 389-94.
215. Olsen AK, Blagbjerg EM, Hansen AK, Marckmann PA. High fat meal activates blood coagulation factor VII in rats. J Nutr 2002; 132: 347-50.
216. Olsen AK, Larsen LF, Blagbjerg EM, Hansen AK, Marckmann PA. High fat meal does not activate blood coagulation factor VII in minipigs. Blood Coagul Fibrinolysis 2001; 12: 117-22.
217. Chu AJ, Moore J, Sampell RM. Daily supplementation with MaxEPA suppresses bacterial endotoxin-inducible procoagulation in dogs. J Surg Res 1997; 71: 93-9.
218. Nieuwenhuys CM, Beguin S, Offermans RF, Emeis JJ, Hornstra G, Heemskerk JW. Hypocoagulant and lipid-lowering effects of dietary n-3 polyunsaturated fatty Acids with unchanged pletelet activation in rats. Arterioscler Thromb Vasc Biol 1998; 18: 1480-9.
219. Kelly FD, Sinclair AJ, Mann NJ, Turner AH, Abedin L, Li D. A stearic acid-rich diet improves thrombogenic and atherogenic risk factor profiles in healthy mates. Eur J Clin Nutr 2001; 55: 88-96.
220. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Haemost 1999; 25: 137-45.
221. Fukutomi T, Naasawa T, Yamamoto H, Adachi I, Watanabe T. The induction of a hypercoagulable state by medroxyprogesterone acetate in breast cancer patients. Jpn J Surg 1990; 20: 665-70.
222. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 1993; 4: 935-42.
223. Nowak-Gottl U, Boos J, Wolff JE, Lill H, Veltmann H, Werber G, et al. Asparaginase decreases clotting factors in vitro: a possible pitfall. Int J Clin Lab Res 1995; 25: 146-8.
224. Bauer KA, Teitel JM, Rosenberg RD. L-asparaginase induces antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb Res 1983; 29: 437-42.
225. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8.
226. Yenicesu I, Uckan D, Cetin M, Tuncer AM, Tezcan I, Gurgey A. Evaluation of coagulation in pediatric bone marrow transplantation patients. Pediatr Transplant 2001; 5: 430-3.
227. Harper PL, Jarvis J, Jennings I., Luddington R, Marcus RE. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990; 5: 39-42.
228. Gordon BG, Haire WD, Patton DF, Manno PJ, Reed EC. Thrombotic complications of BMT: association with protein C deficiency. Bone Marrow Transplant 1993; 11: 61-5.
229. Gordon B, Haire W, Kessinger A, Duggan M, Armitage J. High frequency of antithrombin III and protein C deficiency following autologous bone marrow transplantation for lymphomaBone Marrow Transplant 1991; 8: 497-502.
230. Ito T, Tanouchi J, Kato J, Nishino M, Iwai K, Tanahashi H, et al. Prethrombotic state due to hypercoagulability in patients with permanent transvenous pacemarkers. Angiology 1997; 48: 901-6.
231. Prisco D, Paniccia F, Guarnaccia V, Olivo G, Taddei T, Boddi M, et al. Thrombin generation after physical exercise. Thromb Res 1993; 69: 159-64.
232. Bartsch P, Haeberli A, Straub PW. Blood coagulation after long distance running: antithrombin III prevents fibrin formation. Thromb Haemost 1990; 63: 430-4.
233. Weiss C, Welsch B, Albert M, Friedmann B, Strobel G, Jost J, et al. Coagulation and thrombomodulin in response to exercise of different type and duration. Med Sci Sport Exerc 1998; 30: 1205-10.
234. Shimada K, Kario K, Umeda Y, Hoshide S, Hoside Y, Eguchi K. Early morning surge in blood pressure. Blood Press Monit 2001; 6: 349-53.
235. Petroianu G, Liu J, Helfrich U, Maleck W, Rufer R. Phospholipase A2-induced coagulation abnormalilities after bee sting. Am J Emerg Med 2000; 18: 22-7.
236. McCammon AT, Wright JP, Figueroa M, Nielsen VG. Hemodilution with albumin, but not hextend ®, results in hypercoagulability as assessed by thrombelastography in rabbit: Role of heparin-dependent seroins and factor VIII complex. Anesth Analg 2002; 95: 844-50.
237. Sagripanti A, Carpi A. Natural anticoagulants, aging, and thromboembolism. Exp Gerontol 1998; 33: 891-6.
238. Hager K, Felicetti M, Seefried G, Platt D. Fibrinogen and aging. Aging 1994; 6: 133-8.
239. Hager K, Platt D. Fibrin degradation product concentration (D-dimers) in the course of ageing. Gerontology 1995; 41: 159-65.
240. Pieper CF, Rao KM, Currie MS, Harris TB, Chen HJ. Age, functional status, and racial difference in plasma D-dimer levels in community-dwelling elderly persons. J Geronol (A) Biol Sci Med Sci 2000; 55: M649-57.
241. Hager K, Setzer J, Vogl T, Voit J, Platt D. Blood coagulation factors in the elderly. Arch Gerontol 1989; 9: 277-82.
242. Kario K, Matsuo T. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. Atherosclerosis 1993; 103: 131-8.
243. Kario K, Matsuo T, Nakao K. Factor VII hyperactivity in the elderly. Thromb Haemost 199 1; 65: 25-7.
244. Karin K, Matsuo T. High factor VII activity in the elderly is related to vascular disease through activation of the coagulation system. J Cardiovasc Risk 1994; 1: 165-71.
245. Kario K, Matsuo T, Kobayashi H. Heparin cofactor deficiency in the elderly: comparison with antithrombin III. Thromb Res 1992; 66: 489-98.
246. Sakkinen PA, Cushman M, Psaty BM, Kuller LH, Bajaj SP, Sabharwal AK, et al. Correlation of antithrombin, protein C, protein S and TFPI in healthy elderly cohort. Thromb Haemost 1998; 80: 134-9.
247. Horner AA. Effects of aging on the synthesis of antithrombin-binding sites on heparin chains and heparan sulphate chains in the rat. Biochem J 1995; 312: 245-9.
248. de Jonge E, van der Poll T, Kesecioglu J, Levi M. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. Semin. Thromb Hemost 2001; 27: 667-74.
249. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor FVIIa by antithrombin III and heparin. J Biol Chem 1993; 268: 767-70.
250. Maaroufi RM, Jozefowicz M, Tapon-Bretaudiere J, Fischer AM. Mechanism of thrombin inhibition by antithrombin and heparin cofactor II in the presence of heparin. Biomaterials 1997; 18: 203-11.
251. Liu L, Dewar L, Song Y, Kuleczycky M, Blajchman MA, Fenton JW II, et al. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995; 73: 405-12.
252. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1991; 86: 385-91.
253. Monagle P, Berry L, O'Brodovich H, Andrew M, Chan A. Covalent heparin cofactor II-heparin and heparin cofactor-dermatan sulfate complexes. Characterization of novel anticoagulants. J Biol Chem 1998; 273: 33566-71.
254. Buchanan MR, Liao P, Smith LJ, Ofosu FA. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II. Thromb Res 1994; 74: 463-75.
255. Yamanaga K, Yuuki T, Tsukada M, Koshiba H, Nakajima T, Takechi K, et al. Heparin cofactor II inhibits thrombus formation in arat thrombosis model. Thromb Res 2000; 98: 95-101.
256. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-9.
257. Rogers SJ, Pratt CW, Whinna HC, Church FC. Role of thrombin exosite in inhibition by heparin cofactor II. J Biol Chem 1992; 267: 3613-7.
258. Sheehan JP, Tollefsen DM, Sadler JE. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans. J Biol Chem 1994; 269: 32747-51.
259. Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci USA 2002; 99: 11079-84.
260. Taylor FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor play an important role in protein C activation. Blood 2001; 97: 1685-8.
261. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-80.
262. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. J Biol Chem 1991; 266: 20139-45.
263. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-38.
264. Golino P, Ragni M, Cimmino G, Forte L. Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev 2002; 20: 67-80.
265. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-5.
266. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000; 30: 48-56.
267. Harenberg J, Malsch R, Heene DL. Tissue factor pathway inhibitor: proposed heparin recognition region. Blood Coagul Fibrinolysis 1995; 6(S): S50-60.
268. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediateion of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 6(S): S57-64.
269. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
270. McGee MP, Foster S, Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 1994; 179: 1847-54.
271. Preissner KT, Delvos U, Muller-Berghaus G. Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for heparin-independent mechanism. Biochemistry 1987; 26: 2521-28.
272. Ettelaie C, Howell RM, Bruckdorfer KR. The effect of lipid peroxidation and lipolysis on the ability of lipoproteins to influence thromboplastin activity. Biochim Biophys Acta 1995; 1257: 25-30.
273. Ettelaie C, James NJ, Wilbourn B, Adams JM, Naseem KM, Bruckdorfer KR. The mechanism of inhibition of factor III (thromboplastin) activity by apolipoprotein B-100: protein-protein interactions. Arterioscler Thromb Vasc Biol 1996; 16: 639-47.
274. Ettelaie C, James NJ, Adams JM, Nicola KP, Wilbourn B, Bruckdorfer KR. Identification of a domain in apolipoprotein B-100 that inhibits the procoagulant activity of tissue factor. Biochem J 1998; 333: 433-8.
275. Ettelaie C, Howell RM. The inhibition of thromboplastin by apolipoprotein B and the effect of various lipids. Thromb Res 1992; 68: 175-84.
276. Ettelaie C, Haris PI, James NJ, Wilbourn B, Adams JM, Bruckdorfer KR. Alterations in the structure of apolipoprotein B-100 determine the behaviour of LDL towards thromboplastin. Biochim Biophys Acta 1997; 1345: 237-47.
277. Carson SD. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Letts 1981; 132: 37-40.
278. Carson SD. Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II. J Biol Chem 1987; 262: 718-21.
279. Hecht E. New inhibitors of the first stage of blood clotting process. Nature 1951; 167: 279-80.
280. Hecht E, Shapiro D.Sphingosine as an inhibitor of blood clotting. Science 1957; 125: 1041-41.
281. Hecht E, Landaburu RH, Seegers WH. Sphingosine inhibits blood clotting. Am J Physiol 1957; 189: 203-8.
282. Conkling PR, Patton KL, Hannun YA, Greenberg CS, Weinberg JB. Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding. J Biol Chem 1989; 264: 18440-44.
283. Chu AJ, Lin S-H, Piasentin E. Possible role of Marcks in the cellular modulation of monocytic tissue factor-initiated hypercoagulation. Br J Haematol 2002; 118: 569-76.
284. Stenflo J. Contributions of GIA and EGF-like domains to the functions of vitamin K-dependent coagulation factors. Crit Rev Eukaryotic Gene Expr 1999; 9: 59-88.
285. Pawashe AB, Golino P, Ambrosio F, Ragni M, Pascucci I, Chiariello M, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in sterotic injured rabbit carotid arteries. Cir Res 1994; 74: 56-63.
286. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, et al. Inhibition of endotoxin-indced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
287. Chu AJ, Wang ZG, Raphael UO. IV. Anticoagulant activity of compound 48/80: Inhibition of factor VII activation in Leukemia THP-1 monocytes. J Cardiovasc Pharmacol 2000; 36: 649-55.
288. Kirchhofer D, Moran P, Chiang N, Kim J, Riederer MA, Eigenbrot C, Kelley RF. Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies. Thromb Haemost 2000; 84: 1072-81.
289. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutics. Thromb Haemost 2001; 85: 379-89.
290. Pitlick FA. Concanavalin A inhibits tissue factor coagulation activity. J Clin Invest 1975; 55: 175-9.
291. Chu AJ, Walton MA, Seto A, Fox MJ, Prasad JK, Wang ZG. I. Suppression by compound 48/80 of bacterial endotoxin-inducible monocytic tissue factor activation: direct blockade of Factor VII binding to THP-1 monocytes. Biochim Biophys Acta 1999; 1472: 386-95.
292. Chu AJ, Wang ZG, Fox MJ. III. Instantaneous inhibition by compound 48/80 of tissue factor-initiated coagulation is mediated by the downregulation of factor VII activation. Arch Biochem Biophys 2000; 377: 357-65.
293. Chu AJ, Rauci M, Nwobi OI, Mathews ST, Beydoun S. Novel anticoagulant activity of polybrene: Inhibition of monocytic tissue factor hypercoagulation following bacterial endotoxin induction. Blood Coagul Fibrinolysis 2002; 13: 123-8.
294. Chu AJ, Chen BM, Lin H, Beydoun S. Antimicrobial peptide Buforin I inhibits tissue factor-initiated coagulation. Arch Biochem Biophys 2001; 392: 3-7.
295. Chu AJ, Wang ZG, Raicu M, Ramos N, Beydoun S. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol 2001; 115: 392-9.
296. Chu AJ, Wang ZG, Nwobi OI, Beydoun S. Blockade by ruthenium red of tissue factor-initiated coagulation. Br J Pharmacol 2001; 133: 659-64.
297. Rao LA, Rapaport SI, Hoang AD. Binding of fcator VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-7.
298. Mahdi F, Rehemtulla A, Van Nostrand WE, Bajaj SP, Schmaier AH. Protease nexin-2/amyloid beta protein precursor regulates factor FVIIa and the factor VIIa-tissue factor complex. Thromb Res 2000; 99: 267-76.
299. Higashi S, Matsumoto N, Iwanaga S. Molecular mechansim of tissue factor-mediated acceleration of factor VIIa activity. J Biol Chem 1996; 271: 26569-74.
300. Kirchhofer D, Lipari MT, Moran P. The tissue factor region that interacts with substrates factor IX and factor X. Biochemistry 2000; 39: 7380-7.
301. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechansim of antithrombin III inhibition of factor FVIIa/tissue factor activity on cell surface. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-9.
302. Francischetti IM, Valenzuela JG, Andersen JF, Mather TN, Ribeiro JM. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002; 99: 3602-12.
303. Stanssens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996; 93: 2149-54.
304. Moons AH, Peters RJ, Cate Ht H, Bauer KA, Vlasuk GP, Buller HR, et al. Recombinant Nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, agrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002; 88: 627-31.
305. Ronning HF, Risoen UC, Orning L, Sletten K, Sakariassen KS. Synthetic peptide analogs of tissue factor and factor VII which inhibit factor Xa formation by the tissue factor/factor VIIa complex. Thromb Res 1996; 84: 73-81.
306. Sorensen BB, Rao LV. Interaction of activated factr VII and active site-inhbited activated factor VII with tissue factor. Blood Coagul Fibrinolysis 1998; S(1): S67-71.
307. Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Hedner U, et al. The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagul Fibrinolysis 1998; 9(S1): S21-5.
308. Dennis MS, Eigenbrot C, Skelton NJ, Ultsch MH, Santell L, Dwyer MA, et al. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000; 404: 465-70.
309. Roberge M, Peek M, Kirchhofer D, Dennis MS, Lazarus RA. Fusion of two distinct peptide exosite inhibitors of factor VIIa. Biochem J 2002; 363: 387-93.
310. Kelley RF, Refino CJ, O'Connell MP, Modi N, Sehi P, Lowe D, et al. A soluble tissue factor mutant is a selctive anticoagulant and antithrombotic agent. Blood 1997; 90: 3219-27.
311. Lee GF, Kelley RF. A novel soluble tissue factor variant with an altered factor VIIa binding interface. J Biol Chem 1998; 273: 4149-54.
312. Yang J, Lee GF, Rienderer MA, Kelley RF. Enhnacing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa. Thromb Res 2002; 87: 450-8.
313. Lee GY, Lazarus RA, Kelley RF. Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins. Biochemistry 1997; 36: 5607-11.
314. Jakobsen P, Horneman AM, Persson E. Inhibition of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel 2-aryl substituted pyrid. Bioorg Med Chem 2000; 8: 2803-12.
315. Jakobsen P, Pedersen BR, Persson E. Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel specific 2-aryl sbstituted 4H-3,1-benzoxazin-4-ones. Bioorg Med Chem 2000; 8: 2095-103.
316. Barrow RT, Parker ET, Krishnaswamy S. Inhibition by heparin of human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-800.
317. Sheelan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998; 92: 1616-25.
318. Sheelan JP, Phan TM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001; 40: 4980-9.
319. Fredenburgh JC, Anderson JAM, Weitz JI. Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin. Trends Cardiovasc Med 2002; 12: 281-7.
320. Church WR, Messier TL, Tucker MM, Mann KG. An inhibitory monoclonal antibody to factor X that blocks prothrombin activation but not prothrombinase enzyme assembly. Blood 1988; 72: 1911-21.
321. Grosset AB, Spiro TE, Beynon J, Rodgers GM. Enozaparin, a low-moleculae-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thromb Res 1997; 86: 349-54.
322. Zeerleder S, Manton T, Lammle B, Wuillemin WA. Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res 2002; 105: 441-6.
323. Falkon L, Gari M, Barbanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses. Blood Coagul Fibrinolysis 1998; 9: 137-141.
324. Wellington K, McClellan K, Jarvis B. Reviparin: A review of its efficacy in the prevention and treatment of venous thromboembolism. Drugs 2001; 61: 1185-209.
325. Holmostrom M, Berglund MC, Granquist S, Bran G, Tornebohm E, Lockner D. Fragmin once or twice dail subcutaneously in the treatment od deep venous thrombosis of the leg. Thromb Res 1992; 67: 49-55.
326. Sissi C, Naggi A, Torri G, Palumbo M. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins. Semin Thromb Hemost 2001; 27: 483-7.
327. Olson ST, Bjork I, Bock S. Identification of critical molecular interactions mediating heparin activation of antithrombin. Implications for the design of improved heparin anticoagulants. Trends Cardiovasc Med 2002; 12: 189-205.
328. Waxman L, Smith DE, Arcui KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-96.
329. Jordan SP, Mao SS, Lewis SD, Shafer JA. Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. Biochemistry 1992; 31: 5347-80.
330. Jordan SP, Waxman L, Smith DE, Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990; 29: 11095-100.
331. Mao SS, Huang J, Welebob C, Neeper MP, Garsky VM, Shafer JA. Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human factor Xa. Biochemistry 1995; 34: 5098-103.
332. Gaspar AR, Joubert AM, Crause JC, Neitz AW. Isolation and characterization of an anticoagulant from the salivary glands of the tick, Ornithodoros savignyi. Exp Appl Acarol 1996; 20: 583-98.
333. Ibrahim MA, Ghazy AH, Maharem TM, Khalil MI. Factor Xa (FXa) inhibitor from the nymphs of the camel tick Hyalomma dromedarii. Comp Biochem Physiol B Biochem Mol Biol 2001; 130: 501-12.
334. Faria F, Kelen EM, Sampaio CA, Bon C, Duval N, Chudzinski-Tavassi AM. A new factor Xa inhibitor (lefazin) from the Haementeria depressa leech. Thromb Haemost 1999; 82: 1469-73.
335. Fernandez AZ, Tablante A, Beguin S, Hemker HC, Apitz-Castro R. Draculin, the anticoagulant factor in vampire bat saliva, is a tight-binding, noncompetitive inhibitor of activated factor X. Biochim Biophys Acta 1999; 1434: 135-142.
336. Stark KR, James AA. A factor Xa-directed anticoagulant from the salivary glands of the yellow fever mosquito Aedes adgypti. Exp Parasitol 1995; 81: 321-31.
337. Stark KR, James AA. Salivary gland anticoagulants in culicine and anopheline mosquitos (Diptera: Culicidae). J Med Entomol 1996; 33: 645-50.
338. Cappello M, Valsuk GP, Bergun PW, Huang S, Hotez PJ. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA 1995; 92: 6152-6.
339. Rebello SS, Blank HS, Vlasuk GP, Rote WE, Lucchesi BR. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 1997; 283: 91-9.
340. Seymour JL, Lindquist RN, Dennis Ms, Moffat B, Yansura D, Reilly D, et al. Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of factor Xa. Biochemistry 1994; 33: 3949-58.
341. Mahdi F, Van Nostrand WE, Schmaier AH. Protease nexin-2/amyloid beta protein precursor inhibits factor Xa in the prothrombinase complex. J Biol Chem 1995; 270: 23468-74.
342. Hara T, Kunitada S, Iwamoto M. Dx-9065a, a synthetic and selective factor Xa inhibitor, species difference in its anticoagulant activity. Thromb Haemost 1993; 69: 890-9.
343. Morishima y, Tanabe K, Terada Y, Hara T, Kunitada S. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitior: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997; 78: 1366-71.
344. Rogers KL, Chi L, Rapundalo ST, Kramer JB, Gallagher KP. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis. Basic Res Cardiol 1999; 94: 15-22.
345. Tanabe K, Morishima Y, Shibutani T, Terada Y, Hara T, Shinohara Y, et al. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model. Thromb Haemost 1999; 81: 828-34.
346. Hirayama F, Koshio H, Katayama N, Kurihara H, Taniuchi Y, Sato K, et al. The discovery of YM-60828: A potent, selective and orally-bioavailable factor Xa inhibitor. Bioorg Med Chem 2002; 10: 1509-23.
347. Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H, Matsumoto Y, et al. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally active factror Xa inhibitor and warfarin in mice. Jpn J Pharmacol 1998; 78: 191-7.
348. Wong PC, Crain EJ, Knabb RM, Meade RP, Quan ML, Watson CA, et al. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 2000; 295: 212-8.
349. Chi L, Pen YW, Potoczak R, Gibson-G, Hicks G, Mertz TE, et al. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor. Pharmacology 2002; 64: 76-83.
350. Chu V, Brown K, Colussi D, Gao J, Bostwick J, Kasiewski C, et al. Pharmacological characterization of novel factor Xa inhibitor, FXV673. Thromb Res 2001; 103: 309-24.
351. Chu V, Brown K, Colussi D, Choi YM, Green D, Paula HW, et al. In vitro characterization of a novel factor Xa inhibitot, RPR 130737. Thromb Res 2000; 99: 71-82.
352. Kim B, Koo S, Kim S. A peptide derived from human prothrombin fagment 2 inhibits prothrombinase and angiogenesis. Thromb Res 2002; 106: 81-6.
353. Mounier CM, Hackeng TM, Schaeffer F, Faure G, Bon C, Griffin JH. Inhibition of prothrominase by human secretory phospholipase A2 involves binding to factor Xa. J Biol Chem 1998; 273: 23764-72.
354. Simmelink MJ, Horbach DA, Derksen RH, Meijers JC, Bevers EM, Willems GM, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of cloning factors for catalytic phospholipid surfaces. Br J Haematol 2001; 113: 621-9.
355. Monteiro RQ, Zingali RB. Inhibition of prothrombin activation by Bothrojaracin, a C-type lectin from Bothrops jararaca venom. Arch Biochem Biophs 2000; 382: 123-8.
356. Stringer SE, Gallagher JT. Heapran sulphate. Int J Biochem Cell Biol 1997; 29: 709-14.
357. Scully MF, Ellis V, Kakkar VV. Penson polysulphate: activation of heparin cofactor II or antithrombin III according to molecular weight fractionation. Thromb Res 1986; 41: 489-99.
358. Schoen P, Wielders S, Petitou M, Lindhout T. The effect of sulfation of the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III. Thromb Res 1990; 57: 415-23.
359. Maaroufi RM, Jozefowicz M, Tapon-Bretaudiere J, Jozefonvicz J, Fischer AM. Mechansim of thrombin inhibition by heparin cofactor II in the presence of dermatran sulfates, native or oversulfate, and a heparin-like dextran derivative. Biomaterials 1997; 18: 359-66.
360. Vinazzer H, Stocker K. Heparin cofactor II: experimental approach to a new assay and clinical results. Thromb Res 1991; 61: 235-41.
361. Church FC, Meade JB, Treanor RE, Whinna HC. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 1989; 264: 3618-23.
362. Nishino T, Nagumo T. Anticoagulant and antithrombin activities of oversulfated fucans. Carbohydr Res 1992; 229: 355-62.
363. Hyakawa Y, Hayashi T, Hayashi K, Hayashi T, Ozawa T, Niiya K, et al. Heparin cofactor II-dependent antithrombin activity of calcium spirulan. Blood Coagul Fibrinolysis 1996; 7: 554-60.
364. Guglielmone HA, Agnese AM, Montoya SCN, Cabrera JL. Anticoagulant effect and action mechanism of sulfated flavonoids from Flaveria bidentis. Thromb Res 2002; 105: 183-8.
365. Mourao PA, Boisson-Vidal C, Tapon-Bretaudiere J, Drouet B, Bros A, Fischer A. Inactivation of thrombin by a fucosylated chondroitin sulfate from echinoderm. Thromb Res 2001; 102: 167-76.
366. Carson L, Doctor VM. Mechansism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans. Thromb Res 1990; 58: 367-81.
367. Weitz JI, Young E, Johnston M, Stafford AR, Fredenburgh JC, Hirsh J. Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation 1999; 99: 682-9.
368. Herbert JM, Herault JP, Bernat A, Savi P, Schaeffer P, Driguez PA. SR 123781A, a synthetic heparin mimetic. Thromb Res 2001; 85: 852-60.
369. Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, et al. Anticoagulant and antiprotease profile of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thromb Hemost 2001; 7: 131-40.
370. Rydel TJ, Ravichandran KG, Tulinsky A., Bode W, Huber R, Roitsch C, et al. The structure of a complex of recombinant hirudin and huamn alpha-thrombin. Science 1990; 249: 277-80
371. Rydel TJ, Tulinsky A, Bode W, Huber R. Refined structue of the hirudin-thrombin complex. J Mol Biol 1991; 221: 583-601.
372. De Filippis V, Russo I, Vindigni A, Di Cera E, Salmaso S, Fontana A. Incorporation of noncoded amino acids into the N-terminal domain 1-47 of hirudin yields a highhly potent and selective thrombin inhibitor. Protein Sci 1999; 8: 2213-7.
373. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63.
374. Steiner V, Knecht R, Bornsen KO, Gassmann E, Stone SR, Raschdorf F. Primary structure and function of novel O-hlycosylated hirudins from the leech Hirudinaria manillensis. Biochemistry 1992; 31: 2294-8.
375. De Filippis V, Vindigni A, Altichieri L, Fontana A. Core domain of hirudin from the leech Hirudinaria manillensis: chemical synthesis, purification, and characterization of Trp3 analog of fragment 1-47. Biochemistry 1995; 34: 9552-64.
376. Strube KH, Kroger B, Bialojan S, Otte M, Dodt J. Isolation, sequence analysis, and cloning of haemadin. An anticoagulant peptide from the Indian leech. J Biol Chem 1993; 268: 8590-5.
377. Fuentes-Prior P, Noeske-Jungblut C, Donner P, Schleuning WD, Huber R, Bode W. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc Natl Acad Sci USA 1997; 94: 11845-50.
378. Noeske-Jungblut C, Haendler B, Donner P, Alagon A, Possani L, Schleuning WD. Triabin, a highly potent exosite inhibitor of thrombin. J Biol Chem 1995; 270: 28629-34.
379. van de Locht A, Lamba D, Bauer M, Huber R, Friedrich T, Kroger B, et al. Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J 1995; 14: 5149-57.
380. van de Locht A, Stubbs MT, Bode W, Friedrich T, Bollschweiler C, Hoffken W, et al. The omithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J 1996; 15: 6011-7.
381. Arocas V, Zingali RB, Guillin MC, Bon C, Jandrot-Perrus M. Bothrojaracin: a potent two-site-directed thrombin inhibitor. Biochemistry 1996; 35: 9083-9.
382. Francischetti IM, Monteiro RQ, Gumaraes JA, Francischetti B. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Communi 1997; 235: 259-63.
383. Berry C, Girardot C, Lecoffre C. Effects of synthetic thrombin inhibitor argatroban on fibrin or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-6.
384. Lewis B, Wallis D, Berkowitz S. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-43.
385. Sanderson PE. Small, noncovalent serine protease inhibitos. Med Res Rev 1999; 19: 179-197.
386. Bhattacharya A, Smith GF, Cohen ML. Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation. J Pharmacol Exp Ther 2001; 297: 573-81.
387. Koppert PW, Huijsmans CM, Nieuwenhuizen W. A monoclonal antibody, specific for human fibrinogen, fibrinopeptideA-containing fragmentsand not reacting with free fibrinopeptide A. Blood 1985; 66: 503-7.
388. Ichinose A, Kaetsu H. Molecular approach to structure-function relationship of human coagulation factor XIIII. Method Enzymol 1993; 222: 36-51.
389. Saito M, Asskura H, Yoshida T, Ito K, Okafuji K, Yoshida T, et al. A family factor XIII subunit B deficiency. Br J Haematol 1990; 74: 290-4.
390. AnwarSaito R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-84.
391. Lee SY, Chang SK, Lee IH, Kim YM, Chung SI. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. Thromb Haemost 2001; 85: 464-9.
392. Hsieh K. Thrombin interaction with fibrin polymerization sites. Thromb Res 1997; 86: 301-16.
393. Standeven KF, Ariens RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002; 51; 189-97.
394. Houston DS. Tissue factor- a therapeutic target for thrombotic disorders. Expert Opin Ther Targets 2002; 6: 159-74.
395. Wu Q, Sheehan JP, Tsiang M, Lentz SR, Birktoft JJ, Sadler JE. Single amino acid substitutions dissociate fibrinogen clotting and thrombomodulin-binding activities of human thrombin. Proc Natl Acad Sci USA 1991; 98: 6775-9.
396. Gibbs GS, Coutre SE, Tsiang M, Li WX, Jain AK, Dunn KE, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995; 378: 413-6.
397. Dang QD, Sabetta M, Di Cera E. Selective loss of fibrinogen clotting in loop-less thrombin. J Biol Chem 1997; 272: 19649-51.
398. Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin MC, Iwanaga S. Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry 1992; 31: 7457-62.
399. Dang QD, Guinto ER, Di Cera E. Rational engineering of activity and specificity in a serine protease. Nat Biotechnol 1997; 15: 146-9.
400. Aasrum M, Prydz H. Gene targeting of tissue factor, factor X, and factor VII in mice: their involvement, in embryonic development. Biochemistry (Mosc) 2002; 67: 25-32.
401. Chan JC. Gene targeting in hemostasis. Factor VII. Front Biosci 2001; 6: D98-104.
402. Jordan RE, Kilpatrick J, Nelson RM. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 1987; 237: 777-9.
403. Jordan RE, Nelson RM, Kilpatrick J, Newgren JO, Esmon C, Fournel MA. Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction. J Biol Chem 1989; 264: 10493-500.
404. van Iwaarden F, Acton DS, Sixma JJ, Meijers JC, De Groot PC, Bouma BN. Internalization of antithrombin III by cultured human endothelial cells and its subcellular locatization. J Lab Clin Med 1989; 113: 718-26.
405. Sie P, Dupouy D, Dol F, Boneu B. Inactivation of heparin cofactor II by polymorphonuclear leukocytes. Thromb Res 1987; 47: 657-64.
406. Belaaouaj AA, Li A, Wun TC, Welgus HG, Sharpiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 2000; 275: 27123-28.
407. Cunningham AC, Hasty KA, Enghild JJ, Mast AE. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochem. J 2002; 367: 451-8.
408. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, et al. The C-terminus of tissue factor pathway inhibitor is essentail to its anticaogulant activity. Biochemistry 1991; 30: 10371-6.
409. Shimura M, Wada H, Nakasaki T, Hiyoyama K, Mori Y, Nishikawa M, et al. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1999; 60: 94-8.
410. Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000; 83: 937-43.
411. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999; 81: 589-3.
412. Hasan M, Najjam S, Gordon MY, Gibbs RV, Rider CC. IL-12 is a heparin-binding cytokine. J Immunol 1999; 162: 1064-70.
413. deVisser MCH, Poort SR, Vos HC, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X and the risk of venous thrombosis. Thromb Haemost 2001; 85: 1011-1017.
414. Redondo M, Watzke HH, Stucki B. Coagulation factor II, V, VII, and X, prothrombin gene 20210G-A transition and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-1025.
415. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-20.
416. Drake TA, Cheng J, Chang ACK, Taylor FB. Expression of tissue factor, thrombomodulin and E-selectin in baboons with lethal E. Coli sepsis. Am J Pathol 1983; 142: 1458-63.
417. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74: 165-72.
418. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-4.
419. Kruithof EKO, Mestries JC, Gascon MP, Ythier A. The coagulation and fibrinolytic responses of baboons after in vivo thrombin-generation-effect of interleukine 6. Thromb Haemost 1997; 77: 905-10.
420. Dean RT, Prydz H. Inflammatory particles stimulate thromboplastin production by human monocytes. Thromb Res 1983; 30: 357-67.
421. Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Bailliere Clin Haematol 1999; 12: 343-359.
422. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signaling? Thromb Haemost 2001; 86: 1353-9.
423. Camerer E, Rottingen JA, Iversen JG, Prydz H. Coagulation factor VII and X induce Ca+2 oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271: 29034-42.
424. Wang X, Gjernes E, Prydz H. Factor VIIa induces tissue factor-dependent up-regulation of interleukin-8 in human keratinocyte line. J Biol Chem 2002; 277: 23620-6.
425. Siegbahn A, Johnell M, Rorsman C, Ezban M, Heldin CH, Romistrand L. Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phopholpase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 2000; 96: 3452-8.
426. Jones A, Geczy CL. Thrombin and factor Xa enhance the production of interleukine- 1. Immunology 1990; 71: 236-41.
427. Senden NH, Jeunhomme TM, Heemskerk JW, Wagenvoord R, van't Veer C, Hemker HC, et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998; 161: 4318-24.
428. Riewald M, Kravchenko VV, Petrovan RJ, O'Brien PJ, Brass LF, Ulevitch RJ, et al. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 2001; 97: 3109-16.
429. Breschneider E, Braun M, Fischer A, Wittpoth M, Glusa E, Schror K. Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells. Thromb Haemost 2000; 84: 499-505.
430. Monno R, Grandaliano G, Faccio R, Ranieri E, Martino C, Gesualdo L, Schena FP. Activaed coagulation factor X: a novel mitogenic stimulatus for human mesangial cells. J Am Soc Nephrol 2001; 12: 891-9.
431. Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000; 20: 1374-81.
432. Rauch BH, Bretschneider E, Braun M, Schror K. Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res 2000; 31: 1122-7.
433. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-27.
434. Davey M, Luscher E. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature (London) 1967; 216: 857-8.
435. Naldini A, Sower L, Bocci V, Meyers B, Carney DH. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is link to interferon-induced cellular differentiation. J Cell Physiol 1998; 177: 76-84.
436. Hoffmann M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. Blood Cells Mol Dis 1995; 21: 156-67.
437. Drake WT, Lopes NN, Fenton JW Jr, Issekutz AC. Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration. Lab Invest 1992; 67: 617-27.
438. Kim KY, Kim MY, Choi HS, Jin BK, Kim SU, Lee YB. Thrombin induces IL-10 production in microglia as a negative feedback regulator of TNF-alpha release. Neuroreport 2002; 13: 849-52.
439. Moller T, Hanisch UK, Ransom BR. Thrombin-induced activation of cultured rodent microglia. J Neurochem 2000; 75: 1539-47.
440. Naldini A, Carney DH, Pucci A, Pasquali A, Carraro F. Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. Gen Physiol 2000; 35: 255-9.
441. Marin V, Montero-Julian FA, Gres S, Boulay V, Bongrand P, Farnarier C, Kapalnski G. The IL-6 soluble IL-6R alpha autocrine loop of endothelial activation as an intermediate between acute and chroinc inflammation: an experimental model involving thrombin. J Immunol 2001; 167: 3435-42.
442. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-9.
443. Hou L, Ravenall S, Macey MG, Harriott P, Kapas S, Howells GL. Protease-activated receptors and their role n IL-6 and NF-IL-6 expression in human gingival fibroblasts. J Periodontal Res 1998; 33: 205-11.
444. Shin H, Kitajima I, Nakajima T, Shao Q, Tokioka T, Takaski I, et al. Thrombin receptor mediated signals induce expressions of interleukin 6 and granulocyte colony stimulating factor via NF-kappa B activation in synovial fibroblasts. Ann Rheum Dis 1999; 58: 55-60.
445. Gordon JR, Zhang X, Stevenson K, Cosford K. Thrombin induces IL-6 but not TNFalpha secretion by mouse mast cells: threshold-level thrombin receptor and very low level Fcepsilon RI signaling synergistically enhance IL-6 secretion. Cell Immunol 2000; 205: 128-35.
446. Wakita H, Furukawa F, Takigawa M. Thrombin and trypsin induce granulocyte-macrophage colony-stimulating factor and interleukin-6 gene expression in cultured normal human keratinocytes. Proc Assoc Am Physicians 1997; 109: 190-207.
447. Tokunou T, Ichiki T, Takeda K, Funakoshi Y, Lino N, Shimokawa H, et al. cAMP response element-binding protein mediates thrombin-induced proliferation of vascular smooth muscle cells. Thromb Arterioscler Thromb Vasc Biol 2001; 21: 1759-63.
448. Yosida A, Elner SG, Bian ZM, Kunkel SL, Lukacs NW, Elner VM. Thrombin regulates chemokine induction during human retinal pigment epithelial cell/monocyte interaction. Am J Pathol 2001; 159: 1171-80.
449. Suk K, Cha S. Thrombin-induced interleukin 8 production and its regulation by interferon-gamma and prostaglandin E2 in human monocytic U937 cells. Immunol Lett 1999; 67: 223-7.
450. Marin V, Farnarier C, Gres S, Kapalnski S, So MS, Dinarello CA, et al. The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocytye recruitment. Blood 2001; 98: 667-73.
451. Takata M, Urakaze M, Temaru R, Tamazaki K, Nakamura N, Nobata Y, et al. Pravastatin suppresses the interleukin-8 production induced by thrombin in human arotic endothelial cells cultured with high gucose by inhibiting the p44/42 mitogen activated protein kinase. Br J Pharmacol 2001; 134: 753-62.
452. Kaplanski G, Fabrigoule M, Boulay V, Dinarello CA, Bongrand P, Kaplanski S, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol 1997; 158: 5435-41.
453. Cucina A, Borreli V, Di Carlo A, Pagliei S, Corvino V, Santoro-D'Angelo L, et al. Thrombin induces production of growth factors from aortic smooth muscle cells. J Surg Res 1999; 82: 61-6.
454. Shimizu S, Gabazza EC, Hayashi T, Ido M, Adachi Y, Suzuki K. Thrombin stimulates the expression of PDGF in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000; 279: L503-10.
455. Brandes RP, Viedt C, Nguyen K, Beer S, Kreuzer J, Busse R, Gorlach A. Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. Thromb Haemost 2001; 85: 1104-10.
456. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secreation of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001; 86: 1094-8.
457. Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998; 92: 1259-67.
458. Minami T, Aird WC. Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs. J Biol Chem 2001; 276: 47632-41.
459. Lampugnani MG, Colotta F, Polentarutti N, Pedenovi M, Mantovani A, Dejana E. Thrombin induces c-fos expression in cultured human endothelial cells by a Ca+2-dependent mechansim. Blood 1990; 76: 1173-80.
460. Razin E, Baranes D, Marx G. Thrombin-mast cell interactions. Binding and cell activation. Exp Cell Res 1985; 160: 380-6.
461. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-6.
462. Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H. FDP D-dimer induces the secretion of interleukin-1, urokinase-type-plasminogen activator, and plasminiogen activator inhibitor-2 in a human promonocytic leukiemia cell line. Blood 1991; 77: 94-100.
463. Csala M, Lerant I, Banhegyi G, Kardon T, Puskas F, Mucha I, et al. Prostaglandin-independent stimulation of interleukin-6 production by fibrinogen degradation product D in perfused murine liver. Scand J Immunol 1998; 48: 269-71.
464. Lee ME, Rhee KJ, Nham SU. Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages. Mol Cell 1999; 9: 7-13.
465. Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 2001; 4: 269-75.
466. Lee ME, Kweon SM, Nham SU. Fibrin stimulates microfilament reorganization and IL-1 beta production in human monocytic THP-1 cells. Mol Cell 2001; 11: 13-20.
467. Liu X, Piela-Smith TH. Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 2000; 165: 5255-61.
468. Tollefsen DM. Antithrombin deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York, NY: McGraw-Hill; 2001: 4455-71.
469. Asakura H, Ontachi Y, Mizutani T, Kato M, Ito T, Saito M, et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 2001; 67: 170-5.
470. Key NS, Ely EW. Coagulation inhibition for sepsis. Curr Opin Hematol 2002; 9: 416-21.
471. Zuo XJ, Nicolaidou E, Okada Y, Toyoda M, Jordan SC. Antithrombin III inhibts lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, gamma-IFN and IL-4) in vitro. Transpl Immunol 2001; 9: 1-6.
472. Mansell A, Reinicke A, Worrall DM, O'Neill LA. The seine protease inhibitor antithrombin III inhibits LPS-mediated NF-kappaB activation by TLR-4. FEBS Lett 2001; 508: 313-7.
473. Levi M, van der Poll T, ten Cate H, van Deventer SJH. The cytokine-mediated imblanced between coagulation and anticoagulation mechanism in sepsis and endotoxemia. Eur J Clin Invest 1997; 27: 3-9.
474. Isobe H, Okajima K, Uchiba M, Harada N, Okabe H. Antithrombin prevents endotoxin-induced hyptension by inhibiting the induction of nitric oxide synthesis in rats. Blood 2002; 99: 1638-45.
475. Uchiba M., Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270: L921-30
476. Yamashiro K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Miyamoto K, et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2001; 42: 1553-60.
477. Totzke G, Schobersberger W, Schloesser M, Czechowski M, Hoffmann GJ. Effects of antithrombin III on tumor necrosis factor-alpha and interleukin-1 beta synthesis in vascular smooth cells. J Interferon Cytokine Res 2001; 21: 1063-9.
478. Kaneider NC, Rabensteiner A, Reinisch CM, Dunzendorfer S, Wiedermann CJ. Inhibition of human neutrophil chemotaxis toward interleukine 8 with six cinical antithrombin concentrates in vitro. Intensive Care Med 2002; 28: 1447-52.
479. Wiedermann ChJ, Romisch J. The anti-inflammatory actions of antithrombin III. Acta Med Austriaca 2002; 29: 89-92.
480. Opal SM. Therapeutic rationale for antithrombin III. Crit Care Med 2000; 28: S34-7.
481. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patients. High-dose antithrombin III in severe sepsis: a randomized controlled trail. JAMA 2001; 286: 1869-78.
482. Smith D. Report of the international meeting on Intensive Care Medicine. Rome, Italy. Critical Care 2000; 4: 255-62.
483. Minnema MC, Chang ACK, Jansen PM, Lubbers YTP, Pratt BM, Whittaker BG, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with E. Coli. Blood 2000; 95: 1117-23.
484. Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, et al. Antithrombin III inhibits nuclear factor kappa B activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-20.
485. Barnes PI, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
486. Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-9.
487. Barnard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Russell JA, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29: 2051-9.
488. Barnard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
489. Joyce DE, Grinnell BW. Recombinant human activated protein C attunates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappa B. Crit Care Med 2002; 30: S288-93.
490. Yuksel M, Uchiba M, Okjima K, Okabe H. Activated protein C inhibits LPS-induced production of TNF-α by monocytes through inhibtion of activation of NFκB and MAPK pathways. Thromb Haemost 2001; 85: S508-S516.
491. Schmidt-Supprian M, Murphy C, White B, Lawler M, Kapurniotu A, Voelter W, et al. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. J Eur Cytokine Netw 2000; 11: 407-13.
492. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272: L197-202.
493. White B, Schmidt M, Murrph C, Livingstone W, O'Toole DO, Lawler M, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumor necrosis factor α (TNF-α) production in the THP-1 moncytic cell line. Br J Haematol 2000; 110: 130-34.
494. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Saygh MH, et al. Binding of activated protein C to a specific receptor on human monocuclear phagocytes inhibits intracellular calium signaling and monocyte dependent proliferative responses. Transplanation 1995; 60: 1525-32.
495. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-203.
496. Hooper WC, Phillips DJ, Renshaw MA, Evatt BL, Benson JM. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J Immunol 1998; 16: 2567-73.
497. Hooper WC, Phillips DJ, Renshaw MA. Activated protein C induction of MCP-1 in human endothelial cells: a possible role for edothelial cell nitric oxide synthase. Thromb Res 2001; 103: 209-19.
498. Uchiba M, Okajima K, Murakami K, Nawa H, Okabe H, Takatsuki, K. Recombinant human soluble thrombomodolin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 1995; 74: 1265-70.
499. Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki, K. Recombinant thrombomodulin prevents endotoxin-induced lung injury by inhbiting activation of leukocyts in rats. Am J Physiol 1996; 271: L470-5.
500. Taoka Y, Okajima K, Murakami K, Johno M. Neuroprotection by recombinant thrombomodulin. Thromb Haemost 2000: 83: 462-8.
501. Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K. Effect of urinary thrombomodulin on endotoxin-induced intravascular coagulation and pulmonary vascular injury in rats. Am J Hematol 1997; 54: 118-23.
502. Creasey AA, Chang AC, Fiegen L, Wun TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from E. Coli septic shock. J Clin Invest 1993; 91: 2850-60.
503. Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89: 4268-74.
504. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 1999; 95: 1124-29.
505. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001; 183: 1815-8.
506. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 7742-7.